Copenhagen, 2011-11-01 08:30 CET (GLOBE NEWSWIRE) --
Company Announcement
No.16/2011
Copenhagen, 1 November 2011 - Zealand Pharma A/S (NASDAQ OMX: ZEAL), a Danish biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, announces that the company has signed a Market Maker agreement with Nordea, following which Nordea will make a market on NASDAQ OMX Copenhagen for shares issued by Zealand Pharma. The agreement comes into effect as of today.
According to the agreement, Nordea is obliged on a continuous basis to quote both ask and bid prices with a maximum spread of 3%.
The aim of the agreement is to improve the market conditions for Zealand Pharma’s shares via a more transparent and effective pricing and increased liquidity.
For further information, please contact:
Hanne Leth Hillman, Vice President for IR & Corporate Communication
Tel: +45 5060 3689
About Zealand Pharma
Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biopharmaceutical company based in Copenhagen, Denmark with a mature and growing clinical pipeline of innovative peptide based drugs. The company’s lead product is Lyxumia® (lixisenatide), a once-daily GLP-1 agonist licensed to Sanofi, which has Lyxumia® in late-stage Phase III development for the treatment of type 2 diabetes. Zealand Pharma also has a collaboration with Boehringer Ingelheim covering glucagon/GLP-1 dual agonists, including ZP2929 for the treatment of diabetes and obesity, and a licence agreement with Helsinn Healthcare on elsiglutide, a clinical stage GLP-2 drug for the treatment of chemotherapy- and radiotherapy-induced diarrhea.
Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs with favorable therapeutic attributes, and all drug candidates in its pipeline have been identified through the company’s own drug discovery activities. Zealand Pharma’s products target disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. For further information: www.zealandpharma.com.
